Carregant...
Surgery in oligometastatic NSCLC patients in the targeted therapy era
More than 50% of NSCLC patients present with metastatic disease at first diagnosis, with a median survival of 8–11 months. However, selected patients with oligometastatic disease who receive appropriate local therapy for both the primary lesion and metastases enjoy long-term survival or are even cur...
Guardat en:
| Publicat a: | Lung Cancer Manag |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Medicine Ltd
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310314/ https://ncbi.nlm.nih.gov/pubmed/30643558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2016-0012 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|